CellCentric was formed as a pioneer in epigenetics. An early aggregator of knowledge in the emerging area of understanding of cell fate control mechanisms, with links to over 25 leading international laboratories.
Based on a strong scientific foundation, and having investigated multiple epigenetic-related targets alone and in collaboration (methyltransferases, demethylases, deubiquitinases), the company is now a highly focused asset-centric business. CellCentric’s lead programme is based on the inhibition of the androgen receptor (AR) pathway via a histone acetyl transferase (HAT) target.
The primary application for CellCentric’s novel inhibitors is for prostate cancer and its most aggressive form, castrate-resistant prostate cancer (CRPC). The pathway also has relevance to other cancer types including bladder and breast.